Summary
The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms. We found significantly lower serum melatonin levels in gout patients in the acute phase than in those in the remission phase or in normal individuals. The mRNA expression of melatonin receptor 2 (MT2) was also lower in gout patients than in normal individuals. To verify the in-vivo role of melatonin, a gouty arthritis model was established by intraarticular injection of monosodium urate (MSU, 1 mg) crystals into the paws of C57BL/6 mice. Joint inflammation in the mouse model was evaluated by measuring the thickness of the right paw/left paw, and the inflammation index was determined by examining infiltrating neutrophils with haematoxylin and eosin (H&E) staining. Melatonin was found to reduce both paw thickness and the inflammation index in the mouse model, and melatonin also reduced the mRNA levels of interleukin-1 beta (IL-1β), IL-6 and NLR family pyrin domain containing 3 (NLRP3) inflammasome. To mimic gouty inflammation in vitro, mouse peritoneal macrophages were stimulated with lipopolysaccharides (LPS) plus MSU. Melatonin was revealed to reduce IL-1β secretion by stimulated macrophages. The mRNA expression levels of IL-1β and IL-6 were also inhibited by melatonin. Western blot analysis showed that the expression of NLRP3, caspase-1 and pro-IL-1β was also inhibited by melatonin. In conclusion, our study demonstrated that melatonin alleviated gouty inflammation in vivo and in vitro, and the underlying mechanism may involve inhibiting the assembly of the NLRP3 inflammasome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Change history
04 August 2021
An Erratum to this paper has been published: https://doi.org/10.1007/s11596-021-2423-1
References
Dehlin M, Jacobsson L, Roddy E, et al. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol, 2020, 16(7):380–390
Bevis M, Blagojevic BM, Mallen C, et al. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology (Oxford), 2018,57:1358–1363.
Chen B, Li H, Ou G, et al. Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage. Arthritis Res Ther, 2019,21(1):193–213
Chung YH, Kim HY, Yoon BR, et al. Suppression of Syk activation by resveratrol inhibits MSU crystal-induced inflammation in human monocytes. J Mol Med (Berl), 2019,97(3):369–383
Wahi K, Kodar K, Mc Connell MJ, et al. MSU Crystals Enhance TDB-Mediated Inflammatory Macrophage IL-1β Secretion. Inflammation, 2019,42(3):1129–1136
Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie, 2015,61(2–3):77–84
Slominski AT, Zmijewski MA, Semak I et al. Melatonin, mitochondria, and the skin. Cell Mol Life Sci, 2017,74(21):3913–3925
Rahim I, Djerdjouri B, Sayed RK, et al. Melatonin adminisration to wild-type mice and nontreated NLRP3 mutant mice share similar inhibition of the inflammatory response during sepsis. J Pineal Res, 2017,63(1):12410–12422
Favero G, Franceschetti L, Bonomini F, et al. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int J Endocrinol, 2017,2017:1835195
Wang J, Zhu XX, Liu L, et al. SIRT1 prevents hyperuricemia via the PGC-1a/PPARg-ABCG2 pathway. Endocrine,2016(53):443–452
Bhattacharya S, Patel KK, Dehari D, et al. Melatonin and its ubiquitous anticancer effects. Mol Cell Biochem, 2019,462(1–2):133–155
Cardinali DP. Melatonin: clinical perspectives in neurodegeneration. Front Endocrinol (Lausanne), 2019, 10:480–490
Najafi M, Shirazi A, Motevaseli E, et al. The melatonin immunomodulatory actions in radiotherapy. Biophys Rev, 2017,9(2):139–148
Reiter RJ, Tan DX, Rosales-Corral S, et al. Melatonin mitigates mitochondrial meltdown: interactions with Sirt3. Int J Mol Sci, 2018,19(8):2439–2450
Gursoy AY, Kiseli M, Caglar GS. Melatonin in aging women. Climacteric, 2015,18(6):790–796
Cardinali DP. Melatonin: clinical perspectives in neurodegeneration. Front Endocrinol (Lausanne), 2019, 10:480–489
Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. Int J Mol Sci, 2019,20(5):1223–1233
Yu GM, Kubota H, Okita M, et al. The anti-inflammatory and antioxidant effects of melatonin on LPS-stimulated bovine mammary epithelial cells. PLoS One, 2017,12(5):112–130
Farez MF, Calandri IL, Correale J, et al. Anti-inflammatory effects of melatonin in multiple sclerosis. Bioessays, 2016,38(10):1016–1026
Song Z, Humar B, Gupta A, et al. Exogenous melatonin protects small-for-size liver grafts by promoting monocyte infiltration and releases interleukin-6. J Pineal Res, 2018,65(1):12486–12510
Liu Z, Gan L, Xu Y, et al. Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-κB/GSDMD signal in mice adipose tissue. J Pineal Res, 2017,63(1):10–30
Zhang Y, Li X, Grailer JJ, et al. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res, 2016,60(4):405–414
Cao S, Shrestha S, Li J, et al. Melatonin-mediated mitophagy protects against early brain injury after subarachnoid hemorrhage through inhibition of NLRP3 inflammasome activation. Sci Rep, 2017,7(1):2417–2427
Cao Z, Fang Y, Lu Y, et al. Melatonin alleviates cadmium-induced liver injury by inhibiting the TXNIP-NLRP3 inflammasome. J Pineal Res, 2017,62(3):10–23
Zhang J, Lu X, Liu M, et al. Melatonin inhibits inflammasome-associated activation of endothelium and macrophages attenuating pulmonary arterial hypertension. Cardiovasc Res, 2019,10:312–328
He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci, 2016,41(12):1012–1021
Hoseini Z, Sepahvand F, Rashidi B, et al. NLRP3 inflammasome: its regulation and involvement in atherosclerosis. J Cell Physiol, 2018,233(3):2116–2132
Zhong Z, Liang S, Sanchez-Lopez E, et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature, 2018,560(7717):198–203
Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum, 2009,60(1):281–289
Palazón-Riquelme P, Worboys JD, Green J, et al. USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation. EMBO Rep, 2018,19(10):447–486
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.
Additional information
The present study was supported by the Science and Technology Development Fund of Shanghai Pudong New Area (No. PKJ2018-Y36), PDH-SPFDU Joint Research Fund (RHJJ2018-02), the General Program of Shanghai Municipal Commission of Health and Family Planning (No. 202040479) and the National Natural Science Foundation of China (No. 82071830).
Rights and permissions
About this article
Cite this article
Xiao, Wz., Zhao, L., Cao, L. et al. Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. CURR MED SCI 41, 757–763 (2021). https://doi.org/10.1007/s11596-021-2362-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2362-x